RPTX - Repare Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Montreal,
Canada
Type: Equity
RPTX price evolution
RPTX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $79.82 | $103.22 | $111.27 | $107.37 |
| Short term investments | $128.3 | $133.78 | $112.36 | $142.7 |
| Net receivables | $3.57 | $3.38 | $4.5 | $3.73 |
| Inventory | ||||
| Total current assets | $228.54 | $254.67 | $243.69 | $275.09 |
| Long term investments | ||||
| Property, plant & equipment | $5.42 | $6.48 | $7.54 | $8.61 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.8 | $8.41 | $10.21 | $11.31 |
| Total investments | $128.3 | $133.78 | $112.36 | $142.7 |
| Total assets | $235.34 | $263.08 | $253.9 | $286.41 |
| Current liabilities | ||||
| Accounts payable | $7.18 | $6.83 | $2.4 | $5.44 |
| Deferred revenue | $1.07 | $11.95 | $22.95 | |
| Short long term debt | $1.96 | $2.22 | $2.4 | $2.33 |
| Total current liabilities | $31.45 | $30.57 | $39.08 | $48.97 |
| Long term debt | $0.22 | $0.56 | $1.01 | $1.59 |
| Total noncurrent liabilities | $0.22 | $0.56 | $2.74 | $4.07 |
| Total debt | $2.17 | $2.78 | $3.41 | $3.92 |
| Total liabilities | $31.67 | $31.13 | $41.82 | $53.04 |
| Shareholders' equity | ||||
| Retained earnings | -$354.72 | -$319.95 | -$333.11 | -$305.08 |
| Other shareholder equity | -$0.13 | -$0.11 | $0.03 | -$0.25 |
| Total shareholder equity | $203.68 | $231.95 | $212.08 | $233.37 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $111.27 | $159.52 | $334.43 | $326.4 |
| Short term investments | $112.36 | $184.42 | $7.44 | $7.53 |
| Net receivables | $4.5 | $4.32 | $0.65 | $4.15 |
| Inventory | ||||
| Total current assets | $243.69 | $353.98 | $351.41 | $346.55 |
| Long term investments | ||||
| Property, plant & equipment | $7.54 | $9.6 | $13.1 | $8.62 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.21 | $10.1 | $17.3 | $10.53 |
| Total investments | $112.36 | $184.42 | $7.44 | $7.53 |
| Total assets | $253.9 | $364.07 | $368.71 | $357.09 |
| Current liabilities | ||||
| Accounts payable | $2.4 | $0.46 | $2.3 | $2.25 |
| Deferred revenue | $11.95 | $55.78 | $51.53 | $58.01 |
| Short long term debt | $2.4 | $2.17 | $1.72 | $0.7 |
| Total current liabilities | $39.08 | $78.62 | $35.09 | $11.01 |
| Long term debt | $1.01 | $3.26 | $5.59 | $3.31 |
| Total noncurrent liabilities | $2.74 | $5.94 | $45.2 | $59.24 |
| Total debt | $3.41 | $5.43 | $7.31 | $4 |
| Total liabilities | $41.82 | $84.56 | $80.29 | $70.26 |
| Shareholders' equity | ||||
| Retained earnings | -$333.11 | -$239.31 | -$210.27 | -$103.36 |
| Other shareholder equity | $0.03 | -$0.43 | ||
| Total shareholder equity | $212.08 | $279.52 | $288.42 | $286.83 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.07 | $52.4 | $13.05 | |
| Cost of revenue | ||||
| Gross Profit | $1.07 | $52.4 | $13.05 | |
| Operating activities | ||||
| Research & development | $30.07 | $32.97 | $35.27 | |
| Selling, general & administrative | $8.32 | $8.62 | $8.65 | |
| Total operating expenses | $38.39 | $41.59 | $43.91 | |
| Operating income | -$37.32 | $10.82 | -$30.87 | |
| Income from continuing operations | ||||
| EBIT | -$34.45 | $13.79 | -$27.84 | |
| Income tax expense | $0.33 | $0.63 | $0.19 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$34.77 | $13.16 | -$28.03 | |
| Income (for common shares) | -$34.77 | $13.16 | -$28.03 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $131.83 | $7.6 | $0.14 | |
| Cost of revenue | ||||
| Gross Profit | $131.83 | $7.6 | $0.14 | |
| Operating activities | ||||
| Research & development | $119.07 | $90.05 | $40.09 | |
| Selling, general & administrative | $32.56 | $26.21 | $14.35 | |
| Total operating expenses | $151.63 | $116.26 | $54.44 | |
| Operating income | -$19.8 | -$108.66 | -$54.3 | |
| Income from continuing operations | ||||
| EBIT | -$13.9 | -$108.59 | -$54.74 | |
| Income tax expense | $15.15 | -$1.68 | -$1.32 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$29.05 | -$106.91 | -$53.42 | |
| Income (for common shares) | -$29.05 | -$106.91 | -$53.42 | |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$34.77 | $13.16 | -$28.03 | -$18.88 |
| Operating activities | ||||
| Depreciation | $1.06 | $1.06 | $1.06 | $1.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.52 | $6.47 | $6.36 | $6.38 |
| Total cash flows from operations | -$30.51 | $11.93 | -$28.16 | -$32.87 |
| Investing activities | ||||
| Capital expenditures | -$0.4 | |||
| Investments | $7.12 | -$20.32 | $32.28 | $24.5 |
| Total cash flows from investing | $7.12 | -$20.32 | $31.88 | $24.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.38 | $0.1 | $0.28 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.38 | $0.1 | $0.28 | |
| Effect of exchange rate | -$0 | -$0.04 | $0.07 | -$0.09 |
| Change in cash and equivalents | -$23.4 | -$8.05 | $3.9 | -$8.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$93.8 | -$29.05 | -$106.91 | -$53.42 |
| Operating activities | ||||
| Depreciation | $4.14 | $4.18 | $3.34 | $1.79 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.06 | $19.69 | $12.83 | $2.54 |
| Total cash flows from operations | -$127.16 | $0.32 | -$85.8 | -$6.08 |
| Investing activities | ||||
| Capital expenditures | -$1.94 | -$0.6 | -$1.65 | -$2.24 |
| Investments | $79.98 | -$175.18 | -$0.03 | -$7.53 |
| Total cash flows from investing | $78.04 | -$175.78 | -$1.68 | -$9.76 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.84 | $0.88 | $95.56 | $247.84 |
| Net borrowings | ||||
| Total cash flows from financing | $0.84 | $0.88 | $95.56 | $247.84 |
| Effect of exchange rate | $0.02 | -$0.33 | -$0.05 | -$0.6 |
| Change in cash and equivalents | -$48.25 | -$174.91 | $8.03 | $231.39 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.27 |
| Quick ratio | 7.27 |